Processa Pharmaceuticals is a biopharmaceutical company focused on the development of drug products for patients who have unmet medical need. Co.'s main product, PCS499, is an oral tablet that is an analog (i.e., a compound having a structure similar to that of the approved drug, but differing from it in respect to a certain component of the molecule) of an active metabolite of an approved drug called pentoxifylline (PTX). PTX (Trental®) is for the treatment of patients with intermittent claudication. The main indication under development for PCS499 is Necrobiosis Lipoidica, a chronic, disfiguring condition affecting the skin and the tissue under the skin typically on the lower extremities. The PCSA stock yearly return is shown above.
The yearly return on the PCSA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PCSA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|